Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18415692 | 0.92 | GRM5 (0.36) | GRM5AVPR1BCNR2CXCR3MEN1 | |
| SCHEMBL19865037 | 0.92 | GRM5 (0.36) | GRM5BRAFAVPR1BCNR2MEN1 | |
| SCHEMBL19670122 | 0.87 | GRM5 (0.34) | GRM5BRAFKMT2ARAF1 | |
| SCHEMBL12654230 | 0.84 | GRM5 (0.36) | GRM5BRAFAVPR1BCNR2MEN1 | |
| SCHEMBL19706090 | 0.82 | GPR52 (0.35) | BRAFMAPTRAF1 | |
| SCHEMBL12654526 | 0.80 | MPL (0.42) | GRM5AVPR1BCNR2 | |
| SCHEMBL12654669 | 0.80 | CNR2 (0.50) | GRM5CNR2KMT2A | |
| SCHEMBL12654415 | 0.80 | GRM5 (0.34) | GRM5AVPR1BCNR2MEN1MAPT | |
| SCHEMBL12654432 | 0.79 | FGFR4 (0.43) | GRM5CNR2MEN1MAPTKMT2A | |
| SCHEMBL16238670 | 0.79 | GRM5 (0.34) | GRM5RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885BRAF 3419/4885AVPR1B 3357/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885BRAF 3419/4885AVPR1B 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.